Clinical trials and young adults with inflammatory bowel disease
Health Care TransitionsYoung adults (approximately 18–35 years) with inflammatory bowel disease (IBD) represent a distinct demographic with unique developmental and physiological characteristics, yet they are underrepresented in clinical trials.
Sneha Dave +10 more
doaj +1 more source
Dietary intake of inulin-type fructans in active and inactive Crohn’s disease and healthy controls: a case-control study [PDF]
, 2015 Background and Aims: Prebiotic inulin-type fructans are widely consumed in the diet and may have contrasting effects in Crohn’s disease by stimulating gut microbiota and/or by generating functional gastrointestinal symptoms.
Ailsa L. Hart +13 more
core +1 more source
Metastatic Crohn’s disease despite infliximab therapy [PDF]
Anais Brasileiros de Dermatologia, 2017 Metastatic Crohn’s disease is a rare extraintestinal manifestation of Crohn’s disease. It is characterized by polymorphic skin lesions formed by non-caseating granulomas located on anatomical sites distant from the gastrointestinal tract.
Sara Campos +3 more
doaj +1 more source
The feasibility of wireless capsule endoscopy in detecting small intestinal pathology in children under the age of 8 years: a multicentre European study. [PDF]
, 2009 Objective: To systematically evaluate the feasibility and methodology to carry out wireless capsule endoscopy (WCE) in children
Bufler, Philip +8 more
core +12 more sources
Progress and Clinical Applications of Crohn’s Disease Exclusion Diet in Crohn’s Disease
Gut and LiverCrohn’s disease is a chronic intestinal inflammatory disorder of unknown etiology. Although the pharmacotherapies for Crohn’s disease are constantly updating, nutritional support and adjuvant therapies have recently gained more attention.
Duo Xu +5 more
doaj +1 more source
Human Pathology: Case Reports, 2015 Reactive angioendotheliomatosis (RAE) is a rare cutaneous vascular disorder, usually associated with systemic diseases. RAE has previously been described only in the skin, with the single exception of one case involving the intestine in a patient with ...
Hwajeong Lee, MD +1 more
doaj +1 more source
Efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn’s disease patients who failed infliximab therapy: The Italian society of pediatric gastroenterology, hepatology, and nutrition experience [PDF]
, 2019 Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.
Accomando S. +15 more
core +1 more source
Atypical Perinuclear Antineutrophil Cytoplasmic Antibodies in Patients with Crohn’s Disease
Canadian Journal of Gastroenterology, 1997 Atypical perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) occur in most patients with ulcerative colitis but only in a minority of those with Crohn's disease ...
Hugh J Freeman
doaj +1 more source
Pulmonary Extraintestinal Manifestation of Crohn’s Disease Treated Successfully with Adalimumab
The Korean Journal of Gastroenterology, 2018 Pulmonary extraintestinal manifestation is rare in Crohn’s disease and has been reported in only a few cases. Despite the presence of pulmonary abnormalities in a significant proportion of patients with inflammatory bowel disease, there are only few case
Dongyeol Shin +6 more
doaj +1 more source
, 2009 Purpose of reviewIntestinal tuberculosis (TB) is increasing due partly to the HIV pandemic. Its clinical presentation mimics inflammatory conditions such as Crohn's disease and malignancies, which are becoming more prevalent, so the diagnosis is ...
Donoghue, HD, Holton, J
core +1 more source